standard of care in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 (REV) 1.44 [0.59; 3.51]
1.44 [0.59 ; 3.51 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable deathsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.68 [0.22; 2.09]
FACCT Trial, 2021 (REV) 1.04 [0.48; 2.26]
0.91 [0.48 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV), FACCT Trial, 2021 (REV) 2 0% 586 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 0.83 [0.47; 1.45]
0.83 [0.47 ; 1.45 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1 0% 332 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.21 [0.69; 2.12]
1.21 [0.69 ; 2.12 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1 0% 448 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 (REV) 1.18 [0.86; 1.62]
1.18 [0.86 ; 1.62 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable hospital dischargedetailed results FACCT Trial, 2021 (REV) 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable ICU admissiondetailed results FACCT Trial, 2021 (REV) 0.70 [0.39; 1.26]
0.70 [0.39 ; 1.26 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1.14 [0.38; 3.42]
1.14 [0.38 ; 3.42 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (REV) 1 0% 332 NA not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 13:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
